Gabapentin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Epilepsy Initial: 300 mg once daily on the 1st day, 300 mg bid on the 2nd day, and 300 mg tid on the 3rd day. Alternatively, 300 mg tid on the 1st day. Doses may be further increased in 300 mg/day increments every 2-3 days according to individual response and tolerability. Effective dosing range: 900-3,600 mg daily. Total daily dose must be given in 3 equally divided doses, at max dose interval not exceeding 12 hours. Neuropathic pain Initial: 300 mg once daily on the 1st day, 300 mg bid on the 2nd day, and 300 mg tid on the 3rd day. Alternatively, 900 mg daily in 3 equally divided doses as starting dose. Doses may be further increased in 300 mg/day increments every 2-3 days according to individual response and tolerability. Max: 3,600 mg/day. Restless leg syndrome As gabapentin enacarbil: Modified-release preparation: Moderate to severe: 600 mg once daily at approx 5 pm. Postherpetic neuralgia As gabapentin enacarbil: Modified-release preparation: Initial: 600 mg once daily in the morning for 3 days, then increased to 600 mg bid.
Administration
May be taken with or without food.
Special Precautions
Patients with mixed seizures including absences, compromised respiratory function, respiratory or neurological disease, history of substance abuse (e.g. alcohol, benzodiazepines, cannabis, cocaine, opioids). Concomitant use with opioids. Avoid abrupt withdrawal. Renal impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal function at baseline and periodically thereafter. Assess for signs of multiorgan hypersensitivity and suicidality (e.g. suicidal thoughts, depression, behavioural changes).
Adverse Reactions
Significant: Suicidal ideation and behaviour, neuropsychiatric effects in children (e.g. emotional lability, hostility, changes in behaviour and thinking, hyperkinesia), acute pancreatitis, respiratory depression, anaphylaxis, angioedema. Blood and lymphatic system disorders: Leucopenia, thrombocytopenia. Ear and labyrinth disorders: Vertigo, tinnitus. Eye disorders:Gastrointestinal disorders: Nausea, vomiting, diarrhoea, dry mouth, dental abnormality, dyspepsia, gingivitis, flatulence, constipation. General disorders and administration site conditions: Fatigue, fever, peripheral oedema, abnormal gait, asthenia, malaise. Infections and infestations: Viral infection, pneumonia, otitis media. Injury, poisoning and procedural complications: Accidental injury, fracture. Investigations: Weight gain, decreased WBC. Metabolism and nutrition disorders: Anorexia, increased appetite. Musculoskeletal and connective tissue disorders: Back pain, arthralgia, myalgia. Nervous system disorders: Somnolence, dizziness, headache, ataxia, amnesia, tremor. Psychiatric disorders: Confusion, depression, nervousness, anxiety. Reproductive system and breast disorders: Impotence. Respiratory, thoracic and mediastinal disorders: Dyspnoea, bronchitis, cough, rhinitis. Skin and subcutaneous tissue disorders: Rash, pruritus, acne. Vascular disorders: Hypertension, vasodilatation.
Potentially Fatal: Multiorgan hypersensitivity such as drug reaction with eosinophilia and systemic symptoms (DRESS).
Drug Interactions
Increased risk of CNS depression (e.g. somnolence, sedation and respiratory depression) with opioids (e.g. morphine). May reduce bioavailability with antacids. May reduce renal clearance with cimetidine.
ATC Classification
N03AX12 - gabapentin ; Belongs to the class of other antiepileptics.
Disclaimer: This information is independently developed by CIMS based on gabapentin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in